Every Form 4 that BIOLARGO INC (BLGO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BLGO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BLGO filings page.
BioLargo, Inc. (BLGO) Chief Science Officer and director Kenneth Reay Code acquired 566,261 common shares on September 30, 2026, at $0.08 per share in exchange for a reduction in amounts BioLargo owed him for salary and unreimbursed business expenses. The acquired shares are subject to a lock-up agreement restricting sale until BioLargo reports gross revenue of at least $40 million on a consolidated basis for any reported period, its market capitalization exceeds $300 million, or a change in control occurs. On the same date, Code gifted 2,000,000 common shares.
BioLargo, Inc. President Dennis P. Calvert received 931,886 shares of common stock on September 30, 2026, in exchange for reducing amounts the company owed him for salary and unreimbursed business expenses, at an acquisition price of $0.08 per share. The shares are locked up and restricted from sale until the company reports gross revenue of at least $40 million on a consolidated basis for any reported period, its market capitalization exceeds $300 million, or a change in control occurs. A limited liability company owned and controlled by Calvert also acquired 2,000,000 shares as a gift; reported beneficial ownership following that transaction includes 3,528,695 shares held indirectly through the company.
BioLargo, Inc. director Dennis E. Marshall acquired two options on September 30, 2026. One covers 281,248 shares and replaced an option for 29,605 shares that expired unexercised; the other covers 234,375 shares and was issued as payment for $18,750 in board fees for the most recently completed quarterly period. Both options have an $0.08 exercise price and expire September 30, 2036.
BioLargo, Inc. (BLGO) director Jack B. Strommen received an option to purchase 187,500 common shares on September 30, 2026, with an exercise price of $0.08 per share. The option was issued as payment for $15,000 in fees due for board service during the most recently completed quarterly period under the company's 2024 Equity Incentive Plan. The reported post-transaction share position was 2,771,762 shares, and the option expires September 30, 2036.
BioLargo, Inc. director Christina Elaine Bray acquired an option to purchase 234,375 common shares on September 30, 2026, at an exercise price of $0.0800 per share, expiring September 30, 2036. The option was issued for $18,750 in fees due for board service during the most recently completed quarterly period under BioLargo’s 2024 Equity Incentive Plan. Following the grant, Bray’s reported direct options covered 1,781,075 shares.
BioLargo, Inc. (BLGO) director Linda Park acquired an option award covering 234,375 common shares on September 30, 2026, with an exercise price of $0.08 per share. The option was issued for $18,750 in fees due for board service during the most recently completed quarterly period, under BioLargo’s 2024 Equity Incentive Plan.
BIOLARGO, INC. Chief Science Officer and director Kenneth Reay Code received a grant of 532,567 shares of common stock at an acquisition price of $0.1135 per share. The shares were issued by the company in exchange for reducing amounts owed to him for salary and unreimbursed business expenses.
The new award is subject to a Lock-Up Agreement that restricts any sale until the company reports at least $40 million of gross revenue on a consolidated basis for a reported period, its market capitalization exceeds $300 million, or there is a change in control. Following this grant, Code beneficially owns 26,408,319 shares, including 22,139,012 shares held indirectly through a wholly owned corporation.
BIOLARGO, INC. President and director Dennis P. Calvert reported two stock awards that increased his direct holdings of common stock. On June 30, 2026 he acquired 699,569 shares at $0.1135 per share, and on July 1, 2026 he acquired 219,914 shares at $0.113 per share, both classified as grants or awards rather than open-market purchases.
The shares were issued by the company in exchange for reducing amounts it owed him for salary and unreimbursed business expenses. The awarded shares are subject to a Lock-Up Agreement, restricting sales until the company reports at least $40 million in consolidated gross revenue for any reported period, or its market capitalization exceeds $300 million, or there is a change in control. After these transactions, he directly owns 11,058,108 shares, which include 1,528,695 shares held indirectly through a limited liability company he owns and controls.
BIOLARGO, INC. director Jack B. Strommen received an option grant as part of his board compensation. He was granted options to purchase 132,159 shares of common stock at an exercise price of $0.1135 per share, expiring on June 30, 2036. After this grant, he holds options to purchase a total of 2,584,262 shares. The grant was issued in lieu of $15,000 in fees for his most recently completed quarterly board service under the company’s 2024 Equity Incentive Plan.
BioLargo director Linda Park received a stock option grant as board compensation. She was awarded options to purchase 165,198 shares of common stock at an exercise price of $0.1135 per share. After this grant, she holds options covering a total of 1,546,700 shares.
The option was issued in lieu of $18,750 in cash fees for her most recent quarterly board service, under BioLargo’s 2024 Equity Incentive Plan. This is a non-cash, compensation-related award rather than an open-market stock purchase or sale.
BioLargo director Christina Elaine Bray received a grant of options to purchase 165,198 shares of common stock. The options have an exercise price of $0.1135 per share and were granted as compensation for $18,750 in board fees for the most recently completed quarter under the 2024 Equity Incentive Plan.
Following this grant, she holds options covering a total of 1,546,700 shares. This is a compensation-related award rather than an open-market transaction.
BIOLARGO, INC. director Dennis E. Marshall reported two stock option grants on June 30, 2026. He received an option for 115,741 shares of common stock at an exercise price of $0.1135 per share, granted to replace a prior 22,500-share option that expired unexercised.
He also received a second option for 198,238 shares at the same $0.1135 exercise price as payment for $18,750 of board fees under the 2024 Equity Incentive Plan. Following these awards, his reported derivative holdings in options totaled 5,639,476 options.
BIOLARGO, INC. director Marshall Dennis E received a new stock option grant as part of his board compensation. On June 22, 2026, he was awarded options to purchase 40,909 shares of common stock at an exercise price of $0.11 per share, expiring June 22, 2036. The grant replaces a prior option for 10,000 shares that expired unexercised, and his total option holdings after this adjustment are 5,463,738 options.
BIOLARGO, INC. Chief Science Officer Kenneth Reay Code received a grant of 69,444 shares of common stock at an acquisition price of $0.162 per share. The award was issued in exchange for reduced salary and unreimbursed business expenses.
The shares are subject to a lock-up agreement and cannot be sold until the company reports at least $40 million in gross revenue for any quarter or year, or its market capitalization exceeds $300 million, or there is a change in control. Following this grant, his total holdings are 25,875,752 shares, including 22,139,012 shares held indirectly through a wholly owned corporation.
BIOLARGO, INC. director Jack B. Strommen received an option grant as compensation for board service. He was awarded an Option to Purchase Common Stock covering 92,593 shares at an exercise price of $0.162 per share, with no cash paid for the grant itself.
The option was issued in lieu of $15,000 in director fees for the most recently completed quarter under the company’s 2024 Equity Incentive Plan. Following this grant, Strommen directly holds derivative securities representing 2,452,103 underlying shares, and this option is scheduled to expire on March 31, 2036.
BIOLARGO, INC. director Christina Elaine Bray received an option grant as compensation for board service. She was awarded an option to purchase 115,741 shares of Common Stock at an exercise price of $0.162 per share, issued under the company’s 2024 Equity Incentive Plan.
The option was granted in lieu of $18,750 of cash fees for the most recently completed quarter. After this award, she beneficially holds derivative securities representing 1,381,502 underlying shares directly, reflecting routine, equity-based director compensation rather than an open-market transaction.
Biolargo, Inc. director Linda Park received a stock option grant as board compensation. On the reported date, she was granted an option to purchase 115,741 shares of common stock at an exercise price of $0.162 per share, expiring on March 31, 2036.
The footnote explains this option was issued in lieu of $18,750 in cash fees for her most recently completed quarterly board service, under Biolargo’s 2024 Equity Incentive Plan. Following this grant, her directly held derivative position is reported as 1,381,502 option-linked shares.
BIOLARGO, INC. director Marshall Dennis E received two option grants for common stock as non-cash compensation. He was granted options over 138,889 shares at an exercise price of $0.162 per share, replacing an earlier option on 68,182 shares that had expired unexercised related to $22,500 in prior services.
He also received a new option over 115,741 shares at the same $0.162 exercise price as payment for $18,750 in board fees for the most recently completed quarter under the 2024 Equity Incentive Plan. After these grants, his reported direct holdings rose to 5,432,829 derivative-linked shares, with both options expiring on March 31, 2036.
BioLargo, Inc. reported a new stock option award to its Chief Financial Officer, Charles K. Dargan. On February 1, 2026, he received an option to purchase 300,000 shares of common stock at an exercise price of $0.179 per share. The option becomes exercisable on March 1, 2026 and expires on February 1, 2036. After this grant, he beneficially owned 5,931,668 derivative securities. The filing notes this option was issued as compensation for serving as Chief Financial Officer from February 1, 2026 through January 31, 2027.
BioLargo, Inc. director and Chief Science Officer received 54,803 shares of common stock on 12/31/2025 at an acquisition price of $0.1843 per share. The shares were issued by the company in exchange for a reduction in amounts owed to the reporting person for salary and unreimbursed business expenses.
The newly issued shares are subject to a Lock-Up Agreement that restricts sales until BioLargo reports gross revenue of at least $40 million for any reported period, or its market capitalization exceeds $300 million, or there is a change in control. Following this transaction, the reporting person beneficially owns 25,806,308 shares of BioLargo common stock, including 22,139,012 shares held indirectly through a wholly owned corporation.
BioLargo, Inc. director and President received additional common stock as compensation. On 12/31/2025, the reporting person acquired 130,222 shares of BioLargo common stock at $0.1843 per share, in exchange for a reduction of salary and unreimbursed business expenses. After this transaction, the reporting person beneficially owned 10,523,625 shares of BioLargo common stock, held directly, which includes shares held through a limited liability company that the reporting person owns and controls. The newly issued shares are subject to a lock-up agreement and cannot be sold until BioLargo reports at least $40 million in gross revenue for any reported period, or its market capitalization exceeds $300 million, or there is a change in control of the company.
BioLargo, Inc. director compensation included an equity component for the most recently completed quarterly period. On 12/31/2025, the reporting person received an option to purchase 101,736 shares of common stock at an exercise price of $0.1843 per share. This option was issued in lieu of $18,750 in board fees owed, under BioLargo’s 2024 Equity Incentive Plan.
Following this grant, the reporting person beneficially owned 1,265,761 derivative securities, reported as held directly. The filing indicates the person’s role as a director and that the report is filed for a single reporting person.
BioLargo, Inc. reported that one of its directors received a new stock option grant as part of board compensation. On 12/31/2025, the director was granted an option to purchase 101,736 shares of common stock at an exercise price of $0.1843 per share. The option becomes exercisable on 12/31/2025 and expires on 12/31/2035, giving the director a 10-year window to exercise once vested. After this grant, the director beneficially owned 1,265,761 derivative securities tied to the company’s stock. The filing explains that the option was issued in lieu of $18,750 in fees owed for serving on the board for the most recently completed quarter, under BioLargo’s 2024 Equity Incentive Plan, highlighting the company’s use of equity-based compensation for its directors.
BioLargo, Inc. director reported receiving a stock option grant as compensation for board service. On 12/31/2025, the director was issued an option to purchase 81,389 shares of common stock at an exercise price of $0.1843 per share. This award was given in lieu of $15,000 in fees owed for the most recently completed quarterly period and was granted under the company’s 2024 Equity Incentive Plan. Following this grant, the director beneficially owned 2,359,510 derivative securities, all held directly.
BioLargo, Inc. director reports new stock option grants for board service. A company director filed a Form 4 disclosing two stock option awards dated 12/31/2025. One option to purchase 122,084 shares of common stock at an exercise price of $0.1843 per share was granted to replace an earlier option for 45,000 shares that had compensated $22,500 of services and had recently expired unexercised. A second option to purchase 101,736 shares at $0.17 per share was issued as payment of $18,750 in fees for service on the board for the most recently completed quarter under BioLargo’s 2024 Equity Incentive Plan. Both options are exercisable on 12/31/2025 and expire on 12/31/2035, reflecting equity-based compensation to the director instead of cash.
BioLargo, Inc. (BLGO) reported an insider stock acquisition by a director and Chief Science Officer on a Form 4. On 11/14/2025, the reporting person acquired 313,754 shares of common stock at $0.16 per share through an exchange for accrued salary and unreimbursed business expenses. After this transaction, the insider beneficially owns 25,751,505 common shares, including 22,139,012 shares held indirectly through a wholly owned corporation.
The newly issued shares are subject to a lock-up agreement. They cannot be sold until BioLargo reports at least $40 million in gross revenue for any consolidated reporting period, or its market capitalization exceeds $300 million, or there is a change in control of the company.
BioLargo, Inc. (BLGO) reported that a director and officer who is also its President acquired 310,269 shares of common stock on 11/14/2025 at $0.16 per share. The shares were issued by the company in exchange for a reduction of amounts owed to the insider for salary and unreimbursed business expenses.
The newly issued shares are subject to a lock-up agreement and cannot be sold until BioLargo reports at least $40 million in consolidated gross revenue for any period, or its market capitalization exceeds $300 million, or there is a change in control. Following this transaction, the reporting person beneficially owns 10,393,403 shares in total, including 1,528,695 shares held indirectly through a limited liability company.